Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

详细信息    查看全文

• 作者：Hajime Abe (1)
  Tsuyoshi Mori (1)
  Yuki Kawai (1)
  Hirotomi Cho (1)
  Yoshihiro Kubota (1)
  Tomoko Umeda (1)
  Yoshimasa Kurumi (2)
  Tohru Tani (3)
  
• 关键词：Adjuvant chemotherapy ; Docetaxel ; Early breast cancer ; Feasibility ; FEC
• 刊名：International Journal of Clinical Oncology
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：18
• 期：3
• 页码：487-491
• 全文大小：203KB
• 参考文献：1. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-83 CrossRef
  2. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686-696 CrossRef
  3. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-313 CrossRef
  4. Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-671 CrossRef
  5. Bonadonna G, Zambetti M, Moliterni A et al (2004) Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 22:1614-620 CrossRef
  6. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-354
  7. Spielmann M, Tubiana-Hulin M, Namer M et al (2002) Sequential or alternating administration of docetaxel (Taxotere^?) combined with FEC in metastatic breast cancer: a randomised phase II trial. Br J Cancer 86:692-97 CrossRef
  8. Iwata H, Sato N, Masuda N et al (2011) Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol 41:867-75 CrossRef
  9. Simon R, Norton L (2006) The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 3:406-07 CrossRef
  10. Cardoso F, Ferreira Filho AF, Crown J (2001) Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 21:789-95
  11. Piedbois P, Serin D, Priou F et al (2007) Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2?weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3?weeks. AERO B03 randomized phase II study. Ann Oncol 18:52-7 CrossRef
  12. Puhalla S, Mrozek E, Young D et al (2008) Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol 26:1691-697 CrossRef
  13. Wildiers H, Dirix L, Neven P et al (2009) Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 114:103-12 CrossRef
  14. Cousin S, Mailliez A, Servent V et al (2009) Feasibility of the sequential FEC 100-Taxotere chemotherapy regimen as an adjuvant or neoadjuvant treatment for breast cancer: experience of a single institution. Cancer Res 69(suppl). abstract 4110
  15. Polyzos A, Malamos N, Boukovinas I et al (2010) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 119:95-04 CrossRef
  16. Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531-39 CrossRef
  
• 作者单位：Hajime Abe (1)
  Tsuyoshi Mori (1)
  Yuki Kawai (1)
  Hirotomi Cho (1)
  Yoshihiro Kubota (1)
  Tomoko Umeda (1)
  Yoshimasa Kurumi (2)
  Tohru Tani (3)
  
  1. Division of Breast and General Surgery, Shiga University of Medical Science Hospital, Seta-Tsukinowa, Otsu, Shiga, 520-2192, Japan
  2. Department of Comprehensive Surgery, Shiga University of Medical Science, Otsu, Japan
  3. Department of Surgery, Shiga University of Medical Science, Otsu, Japan
  
• ISSN：1437-7772

文摘

Background The tolerance and safety associated with the administration order of the anthracycline and taxane drugs have not been evaluated. Patients and methods Breast cancer patients with node-positive or high-risk patients with node-negative were eligible. The feasibility and toxicity were evaluated in the following regimens—arm A, 3 courses of fluorouracil 500?mg/m2, epirubicin 100?mg/m2 and cyclophosphamide 500?mg/m2 (FEC) followed by 3 courses of docetaxel 100?mg/m2 (DOC); arm B, 3 courses of DOC followed by 3 courses of FEC. Results Forty-two patients were registered. The relative dose intensity was 94.2?% for FEC and 97.8?% for DOC in arm A, and 98.9?% for DOC and 95.2?% for FEC in arm B. In arm A, grade 3 or higher hematological toxicity was observed in nine patients, and febrile neutropenia developed in three patients with FEC. In arm B, grade 3 or higher hematological toxicity was observed in seven patients, but febrile neutropenia was not noted in any patient. Conclusion The regimens in both arms A and B were safe regarding adjuvant chemotherapy for early breast cancer. However, DOC followed by FEC might be more tolerable. Further studies will maximize the results obtained with DOC followed by FEC.